NIH IGNITE Program — R61/R33 Phased Neurotherapeutic Grants
Supports early neurotherapeutic translation through milestone-based translational funding.
The NINDS IGNITE program — Innovation Grants to Nurture Initial Translational Efforts — provides milestone-gated, phased R61/R33 funding for early-stage neurotherapeutic development, serving as the primary feeder into the later-stage NIH Blueprint Neurotherapeutics Network for small molecules (BPN) and BPN-Biologics. Three active NOFOs cover distinct development stages: PAR-25-059 (assay developme…
Early-stage neurotherapeutic development including assay development, model system validation, and agent characterization for small-molecule and biologic candidates targeting neurological diseases.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline